Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study

Effect of atomoxetine on quality of life and family burden: results from a randomized, placebo-controlled, double-blind study in children and adolescents with ADHD and comorbid oppositional defiant or conduct disorder

“…While previous studies have used other generic instruments such as the Child Health Questionnaire (CHQ) or the parent-rated Child Health and Illness Profile-Child Edition (CHIP-CE) to measure QoL [3,6,22,23,[40][41][42][43][44], this is the first placebo-controlled study that has used the KINDL-R for this purpose. In this sample, QoL was clearly impaired at baseline as determined by KINDL-R scores (Table 3) [26].…”

“…Both short-and long-acting methylphenidate (MPH) formulations are effective in ADHD patients with concomitant ODD or related aggressive behavior [14,[18][19][20][21]. In contrast, only a few studies have investigated the effect of treatment with atomoxetine on comorbid ODD or CD [22,23]. Therefore, this study was conducted to evaluate the efficacy and tolerability of atomoxetine in children and adolescents with ADHD and comorbid ODD or CD.…”

Guanfacine Extended Release Adjunctive to a Psychostimulant in the Treatment of Comorbid Oppositional Symptoms in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder

“…In contrast, a randomized controlled study that also examined a population of children with diagnoses of both ADHD and ODD (n = 226) found significantly greater changes from baseline on the ODD subscale of the Swanson, Nolan, and Pelham Rating Scale-Revised with atomoxetine than with placebo in an overall repeated-measures analysis ( p = 0.01), although a last-observationcarried-forward analysis found no significant difference between atomoxetine-treated and placebo-treated groups (Bangs et al 2008). The results of additional studies of the effects of atomoxetine on oppositional symptoms in patients with ADHD are similarly inconsistent (Dell'Agnello et al 2009;Hazell et al 2009;Waxmonsky et al 2010;Dittmann et al 2011;Waxmonsky et al 2011;van Wyk et al 2012). Finally, a study of clonidine XR as adjunctive therapy to psychostimulants found significant reductions in mean CPRS total scores compared with placebo, but did not find similar significant reductions on the CPRS oppositional subscale (Kollins et al 2011).…”

“…Historically, monotherapy studies of psychostimulants and of atomoxetine for the treatment of oppositional symptoms have yielded mixed efficacy results (Kaplan et al 2004;Spencer et al 2006;Bangs et al 2008;Lopez et al 2008;Dell'Agnello et al 2009;Hazell et al 2009;Waxmonsky et al 2010;Dittmann et al 2011;Marchant et al 2011;Waxmonsky et al 2011;van Wyk et al 2012). For example, in a randomized, double-blind, parallelgroup, placebo-controlled study conducted in children and adolescents with ODD with or without coexisting ADHD (n = 308), in the overall study population, mixed amphetamine salts (extended release) were associated with significant improvements in parent and teacher ratings on the ODD subscale of the Swanson, Nolan, and Pelham-IV ( p < 0.05) (Spencer et al 2006).…”

Pantogam augmentation in hyperkinetic behavior disorder treatment

“…В этих случаях наблюдаются не только более выраженные и стойкие проявления гиперактивности, нарушения вни-мания и импульсивности, но и вспыльчивость, агрессив-ность, конфликтность, что существенно отражается на качестве жизни и уровне социального функционирования больных. Существуют определенные трудности лечения данной категории по сравнению с более «чистыми» вари-антами гиперкинетических нарушений [7][8][9]. В совре-менных клинических руководствах традиционно реко-мендуется сочетание препаратов, специально предназна-ченных для лечения СДВГ с антипсихотиками [10].…”